Clinical stage pharmaceutical cannabinoid and psychedelics company Incannex has engaged Eurofins to manufacture ReneCann Therapeutic Topical Application for immune disordered skin diseases.

Incannex Healthcare (ASX:IHL) has again teamed with multinational contract development and manufacturing  organisation (CDMO) Eurofins Scientific (Eurofins) to manufacture ReneCann therapeutic for topical applications.

ReneCann is IHL’s proprietary topical cannabinoid formulation for treatment of skin conditions caused by disorders of the immune system, including vitiligo, psoriasis, and atopic dermatitis, otherwise known as eczema.

The ReneCann formulation is commercially protected by granted and pending patents and was acquired by IHL as part of the APIRx acquisition.

The formulation combines Cannabigerol (CBG) and Cannabidiol (CBD). CBG is a non-psychoactive cannabinoid with potent anti-inflammatory properties.

A previous version of ReneCann was used in an in-human proof of concept study with dosing over a 6-week period.

The study was conducted at the Maurits Clinic in The Netherlands and led by a world-renowned dermatologist Dr Marcus Meinardi.

In the study, ReneCann reduced disease scores in patients with each of the target skin diseases.

Patients with vitiligo, psoriasis and atopic dermatitis were observed to experience improvements in symptoms of 10%, 33% and 22% respectively.

Treatment for common conditions

Results for study participants with vitiligo are highly encouraging, partly because the disease incidence is high at 0.5-1.0% of the global population and treatments are limited.

Vitiligo is observed when pigment-producing cells (melanocytes) stop producing melanin, causing the loss of skin colour in patches and the discoloured areas generally become larger over time.

ReneCann was associated with re-pigmentation (usually perifollicular or from the borders of the lesion) and efficacy lasted for weeks eventually before depigmentation recurred.

Product to advance clinical trials

The ReneCann Drug product will be used in clinical trials confirming the safety and therapeutic effect of ReneCann in vitiligo, psoriasis, and atopic dermatitis.

Data on the quality and stability of ReneCann generated as part of this project at Eurofins will be used in the chemistry and manufacturing control modules of future regulatory packages with the US Food and Drug Administration (FDA).

ReneCann also has the potential to be assessed for efficacy in other diseases where topical application may provide a benefit over conventional oral dosed cannabinoid formulations.

IHL chief scientific officer Dr Mark Bleackley said production of ReneCann adds a new route of cannabinoid delivery to the IHL portfolio, opening the possibility for direct application of cannabinoid medicines to affected areas in dermatological conditions.

“ReneCann is also IHL’s first product to incorporate CBG, a minor cannabinoid,” he said.

“Expansion into minor cannabinoids provides us the opportunity to explore different activity profiles of this diverse family of molecules across a range of new therapeutic areas.”

Building a strong partnership

Last week IHL announced Eurofins would also manufacture its two distinct medicated chewable products designed to treat nicotine and opioid addiction disorders.

The CannQuit products are combination drug assets with associated granted patents and patent applications that were also transferred to IHL following the acquisition of APIRx.

CannQuit-N (Nicotine) combines nicotine gum with CBD. The nicotine gum market is reportedly worth about US$5B per annum, and IHL is trying to disrupt it with its invention.

Pharmaceutical product manufacturer, Eurofins is one of the global independent market leaders in the support of clinical studies, as well as in BioPharma contract development and manufacturing.

This article was developed in collaboration with Incannex Healthcare, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.